Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2004

Open Access 01-12-2004 | Research article

Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study

Authors: F Fusun Bolukbas, Hasan Kilic, Cengiz Bolukbas, Mahmut Gumus, Mehmet Horoz, Nazım S Turhal, Birsel Kavakli

Published in: BMC Cancer | Issue 1/2004

Login to get access

Abstract

Background

Serum leptin level is associated with appetite and energy expenditure in healthy individuals. We aimed to evaluate the serum leptin concentration and the other factors which may be associated with weight loss in patients with advanced gastrointestinal cancer.

Methods

Forty-four patients with advanced gastrointestinal cancer (25 gastric and 19 colorectal cancer) and 25 healthy controls were enrolled. Serum leptin levels were measured as ng/ml via enzyme linked immuno-sorbent assay (ELISA) method in all subjects. The difference in serum leptin concentration between cancer and control group, the factor associated with its serum level and the relationship between serum leptin concentration and weight loss was evaluated.

Results

Serum leptin concentration of cancer group was significantly lower than controls (p = 0.002). Female subjects had significantly higher serum leptin concentration than male subjects in control group (p = 0.01), while not in cancer group (p > 0.05). Serum leptin concentration was significantly related with gender in controls (p = 0.023, β = 0.479), while no gender difference was observed in cancer group (p > 0.05). No relationship was found between serum leptin concentration and weight loss percentage in cancer group in linear regression analysis (p > 0.05). No significant difference was observed in serum leptin concentrations between colon and gastric cancer sub-groups (p > 0.05).

Conclusion

Independently from the site of gastrointestinal tract, serum leptin concentration in advanced gastrointestinal cancer is lower than controls and it is not a determinant factor in weight loss. In contrast to healthy subjects, gender does not effect the serum leptin concentration in patients with advanced gastrointestinal cancer.
Literature
1.
Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV: Leptin: the tale of an obesity gene. Diabetes. 1996, 45: 1455-1462.CrossRefPubMed
2.
3.
Friedman JM: Leptin, leptin receptors and the control of body weight. Eur J Med Res. 1997, 2: 7-13.PubMed
4.
5.
Stephens T, Basinski M, Bristow P, Bue-Valleskey J, Burgett S, Craft L, Hale J, Hoffmann J, Hsiung H, Kriauciunas A, MacKellar W, Rosteck P, Schoner B, Smith D, Tinsley F, Zhang X, Heiman M: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995, 377: 530-532. 10.1038/377530a0.CrossRefPubMed
6.
7.
Ovesen L, Hannibal J, Mortensen EL: The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer. 1993, 19: 159-167.CrossRefPubMed
8.
McMillan DC, O'Gorman P, Fearon KC, McArdle CS: A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia of gastrointestinal cancer patients. Br J Cancer. 1997, 76: 788-790.CrossRefPubMedPubMedCentral
9.
McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer. 1998, 31: 101-105.CrossRefPubMed
10.
Hood AF, Soter NA, Rappeport J, Gigli I: Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation. Arch Dermatol. 1977, 113: 1087-1091. 10.1001/archderm.113.8.1087.CrossRefPubMed
11.
Meisser A, Cameo P, Islami D, Campana A, Bischof P: Effects of interleukin-6 (IL-6) on cytotrophoblastic cells. Mol Hum Reprod. 1999, 5: 1055-1058. 10.1093/molehr/5.11.1055.CrossRefPubMed
12.
Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A: Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 2000, 5: 421-426.PubMed
13.
Simons JP, Schols AM, Campfield LA, Wouters EF, Saris WH: Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond). 1997, 93: 273-277.CrossRef
14.
Wallace AM, Sattar N, McMillan DC: Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res. 1998, 4: 2977-2979.PubMed
15.
Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M: Radioimmunoassay of leptin in human plasma. Clin Chem. 1996, 42: 942-946.PubMed
16.
Mantzoros CS, Moschos S, Avramopoulos I, Kaklamani V, Liolios A, Doulgerakis DE, Griveas I, Katsilambros N, Flier JS: Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab. 1997, 82: 3408-3413. 10.1210/jc.82.10.3408.PubMed
17.
Moses AG, Dowidar N, Holloway B, Waddell I, Fearon KC, Ross JA: Leptin and its relation to weight loss, ob gene expression and the acute-phase response in surgical patients. Br J Surg. 2001, 88: 588-593. 10.1046/j.1365-2168.2001.01743.x.CrossRefPubMed
18.
Barber MD, McMillan DC, Wallace AM, Ross JA, Preston T, Fearon KC: The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer. 2004, 90: 1129-1132. 10.1038/sj.bjc.6601712.CrossRefPubMedPubMedCentral
19.
Brown DR, Berkowitz DE, Breslow MJ: Weight loss is not associtated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab. 2001, 86: 162-166. 10.1210/jc.86.1.162.CrossRefPubMed
20.
Wigmore SJ, Plester CE, Ross JA, Fearon KC: Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg. 1997, 84: 196-197. 10.1046/j.1365-2168.1997.02525.x.CrossRefPubMed
Metadata
Title
Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study
Authors
F Fusun Bolukbas
Hasan Kilic
Cengiz Bolukbas
Mahmut Gumus
Mehmet Horoz
Nazım S Turhal
Birsel Kavakli
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2004
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-4-29

Other articles of this Issue 1/2004

BMC Cancer 1/2004 Go to the issue

Research article

Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities

Research article

Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression

Case report

Squamous cell carcinoma developing in the scar of Fournier's gangrene – Case report

Research article

Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis

Research article

Antitumor effectiveness of different amounts of electrical charge in Ehrlich and fibrosarcoma Sa-37 tumors

Research article

Characterization of a novel large deletion and single point mutations in the BRCA1gene in a Greek cohort of families with suspected hereditary breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits